Zelig Eshhar, Who Engineered Immune Cells to Fight Cancer, Dies at 84
Zelig Eshhar, Who Engineered Immune Cells to Fight Cancer, Dies at 84
He made a conceptual leap in immunotherapy by creating a hybrid T-cell, known as CAR-T, that was genetically modified to destroy cancer cells.
Read the full article on NY Times Science
Truth Analysis
Analysis Summary:
The article is highly accurate and presents a neutral perspective on Zelig Eshhar's contribution to immunotherapy. All key claims are supported by multiple reliable sources, confirming his role in creating CAR-T cells and their function in fighting cancer. There is no discernible bias in the reporting.
Detailed Analysis:
- Claim: Zelig Eshhar created a hybrid T-cell, known as CAR-T, that was genetically modified to destroy cancer cells.
- Verification Source #1: Confirms Eshhar's work on engineering cells to recognize and destroy cancer cells.
- Verification Source #2: States that Eshhar proved immune cells could be engineered to fight cancer.
- Verification Source #3: Identifies Eshhar as the 'father of CAR-T cells'.
- Verification Source #4: Confirms Eshhar's work on engineering cells to recognize and destroy cancer cells.
- Verification Source #5: Mentions Eshhar's work on TCR-engineered T-cells as a central weapon against cancer.
- Assessment: Supported by multiple sources.
Supporting Evidence/Contradictions:
- Source 3: 'The father of CAR T cells, Prof. Zelig Eshhar, passed away'
- Source 2: 'Zelig Eshhar's research reshaped the world of oncology. He proved that immune cells could be engineered to not just fight cancer, but to...'